Design Therapeutics, Inc.
DSGN
$5.41
$0.214.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -89.02% | 26.49% | |||
| Gross Profit | 89.02% | -26.49% | |||
| SG&A Expenses | 15.67% | 11.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.64% | 22.31% | |||
| Operating Income | -5.64% | -22.31% | |||
| Income Before Tax | -7.72% | -29.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.72% | -29.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.72% | -29.77% | |||
| EBIT | -5.64% | -22.31% | |||
| EBITDA | -5.72% | -22.45% | |||
| EPS Basic | -7.53% | -29.61% | |||
| Normalized Basic EPS | -7.53% | -29.63% | |||
| EPS Diluted | -7.53% | -29.61% | |||
| Normalized Diluted EPS | -7.53% | -29.63% | |||
| Average Basic Shares Outstanding | 0.18% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||